Ipsen SA (Ipsen) focuses on the development and commercialization of novel solutions for targeted debilitating diseases including cancer, endocrine and neurological diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company focuses on three therapeutic areas of cancer, neuroscience, and rare diseases, developing new and differentiated therapies in areas of high unmet medical need. It invests to develop and deliver innovative therapeutic solutions for patients’ benefit. In FY2022, the company’s R&D expenses amounted to EUR445.3 million, which grew 3.9% YoY. It accounted for 14.1% of annual sales revenue. The company has approximately 702 employees engaged in the R&D activities. It operates four R&D centers in Paris-Saclay, France; Cambridge, the US; Shanghai, China; and Oxford, the UK. It has additional R&D centers located at Beijing, China; Berlin, Germany; Dreux, France; Dublin, Ireland; and Wrexham, the UK. Ipsen’s pipeline portfolio comprises of both lifecycle management of its well-established products and development of innovative new molecules, including neurotoxins, small molecules and theragnostic. It also collaborates with leading academic research, medical and technology centers globally.